Comparative pharmacokinetics of Racivir®, (±)-β-2′, 3′-dideoxy-5-fluoro-3′-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 2, 2005, Pages 117-127

  Hurwitz, Selwyn J ^a   Otto, Michael J ^b   Schinazi, Raymond F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHARMASSET INC   (United States)

Author keywords

(+) FTU; Allometric scaling; Antiretroviral nucleoside; Cytidine deaminase; FTC; Interspecies pharmacokinetics; Racivir

Indexed keywords

ANTIVIRUS AGENT; CYTIDINE DEAMINASE; DRUG METABOLITE; EFAVIRENZ; EMTRICITABINE; STAVUDINE; 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE; DRUG DERIVATIVE; ZALCITABINE;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DEAMINATION; DOG; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUSE; NONHUMAN; PREDICTION; PREGNANCY; PRIORITY JOURNAL; RABBIT; RAT; RAT STRAIN; RHESUS MONKEY; STATISTICAL SIGNIFICANCE; ANIMAL; CLINICAL TRIAL; COMPARATIVE STUDY; MACACA; PHASE 1 CLINICAL TRIAL; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIVIRAL AGENTS; DOGS; FEMALE; HIV INFECTIONS; HUMANS; MACACA MULATTA; MALE; PREGNANCY; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; ZALCITABINE;

EID: 23244465884     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600204     Document Type: Article

References (37)

1. Abobo CV, Ni L, Schinazi RF, Liotta DC ScBoudinot FD (1994) Pharmacokinetics of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine in rats. Journal of Pharmaceutical Sciences 83:96-99.
2. Barry MG, Khoo SH, Veal GJ, Hoggard PG, Gibbons SE, Wilkins EG, Williams O, Breckcnridge AM & Back DJ (1996) The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10:1361-1367.
3. Black PL, Ussery, MA, Otto MJ, Stuyver, L, Hurwitz, SJ, Barnett T, Mowrey, JO, Tharnish PM, Boudinot FD & Schinazi RF (2001) Potent antiviral activity of Racivir in the HuPBMC-SCID mouse model of HIV infection. Antiviral Research 51:A017.
4. Camiener GW & Smith CG (1965) Studies of the enzymatic deamination of cytosine arabinoside-I. Enzyme distribution and species specificity. Biochemical Pharmacology 14:1405-1416.
5. Choi WB, Wilson LJ, Yeola S, Liotta DC & Schinazi RF (1991) In situ complexation directs the stereochemistry of N-glycosylation m the synthesis of oxathiolanyl and dioxolanyl nucleoside analogs. Journal of the American Chemical Society 113:9377-9379.
6. Chu CK, Schinazi RF, Ahn MK, Ullas GV & Gu ZP (1989) Structure-activity relationship of pyrimidme nucleosides as antiviral agents for human immunodeficiency type 1 in peripheral blood mononuclear cells. Journal of Medical Chemistry 32:612-617.
7. Cosford NDP & Schinazi RF (1991) Selenium nucleophiles for the preparation of antiviral nucleosides. Journal of Organic Chemistry 56:2161-2165.
8. Cui L, Schinazi RF, Gosselin G, Imbach JL, Chu CK, Rando RF, Revankar GR & Sommadossi J-P (1996) Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochemical Pharmacology 52:1577-1584.
9. Darque A, Valette G, Rousseau F, Wang LH, Sommadossi J-P & Zhou XJ (1999) Quantitation of intracellular triphosphate of cmtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy 43:2245-2250.
10. Doong SL, Tsai CH, Schinazi RF, Liotta DC & Cheng Y-C (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proceedings of the National Academy of Sciences, USA 88:8495-8499.
11. Feng JY, Shi J, Schinazi RF & Anderson KS (1999) Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB Journal 13:1511-1517.
12. Frick LW, St John L, Tavlor LC, Painter GR, Furman PA, Liotta DC, Furfine ES & Nelson DJ (1993) Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-tluorol-[2-(bydroxymethyl)-1,3-oxathiolan-5- yl]cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrobial Agents & Chemotherapy 37:2285-2292.
13. Frick LW, Lambe CU, St John L, Taylor LC &, Nelson DJ (1994) Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2′R,5′S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3- oxathiolan-5-yl]-cytosme, an agent active against human immunodeficiency virus and human hepatitis B virus. Antimicrobial Agents & Chemotherapy 38:2722-2729.
14. Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA, Turtle JV, Miller WH, Condreay L, Averett DR, Schinazi RF & Painter GR (1992) The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymcthyl)-1,3-oxythiolan 5-yl]cytosine (FTC). Antimicrobial Agents & Chemotherapy 36:2686-2692.
15. Gibaldi M & Perrier D (1982) Pharmacokinetics. 2nd edn; pp.113-144. New York: Marcel Decker.
16. Hoong LK, Strange LE, Liotta DC, Koszalka GW, Burns CL & Schinazi RF (1992) Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2′,3′-dideoxy-5-fluoro-3′-thiacytidine (FTC) and related compounds. Journal of Organic Chemistry 57:5563-5565.
17. Hurwitz SJ & Schinazi RF (2002) Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. Antiviral Research 56:115-127.
18. Hussev EK, Donn K, Daniel MJ, Hall ST, Harker AJ & Evans GL (1994) Interspecies scaling and pharmacokinetic modeling of 3TC in humans. Journal of Clinical Pharmacology 34:975-977.
19. Ibrahim SS & Boudinot FD (1989) Pharmacokinetics of 2′,3′dideoxycytidine in rats: application to interspecics scale-up. Journal of Pharmaceutical Sciences 41:829-834.
20. Ings RM (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20:1201-1231.
21. Korba BE, Schinazi RF, Cote P, Tennant BC & Gerin JL (2000) Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrobial Agents & Chemotherapy 44:1757-1760.
22. Lederman SA & Rosso P (1981) Effects of obesity, food restriction and pregnancy on fetal and maternal weight and on body composition in rats. Journal of Nutrition 111:2162-2171.
23. Marcelin AG, Dclaugerrc C, Wirden M, Viegas P, Simon A, Katlama C & Calvez V (2004) Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. Journal of Medical Virology 72:162-165.
24. Metzler CM (1987) Extended least squares (ELS) for pharmacokinetic models. Journal of Pharmaceutical Sciences 76:565-571.
25. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Serini D, Morlat P, Journot V, Decazes JM & Chene G (2000) Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 182:599-602.
26. Moore LF, Ascenzi MA, Tennant BC, Shi J, Schinazi RF & Boudinot FD (1997) Stereoselective pharmacokinetics and metabolism of 2′-deoxy-5- fluoro-3′-thiacytidine (FTC) in woodchucks. Pharmaceutical Research 14:S74.
27. Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. Journal of Pharmaceutical Sciences 75:1028-1040.
28. Patel BA, Boudinot FD, Schinazi RF, Gallo JM & Chu CK (1990) Comparative pharmacokinetics and interspecies scaling of 3′-azido- 3′-deoxythymidine (AZT) in several mammalian species. Journal of Pharmacobio-Dynamics 13:206-211.
29. Rocci ML, & Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Computer Methods & Programs in Biomedicine 16:203-216.
30. Ray AS, Murakami E, Peterson CN, Shi J, Schinazi RF & Anderson KS (2002) Interactions of enantiomers of 2′,3′-didehydro-2′, 3′-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antiviral Research 56:189-205.
31. Ray AS, Schinazi RF, Murakami E, Basavapathruni A, Shi J, Zorca SM, Chu CK & Anderson KS (2003) Probing the mechanistic-consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase. Antiviral Chemistry & Chemotherapy 14:115-125.
32. Schinazi RF, McMillan AD, Cannon R, Mathis RM, Lloyd A, Peck LA, Sommadossi J-P, St Clair M, Wilson J, Furman PA, Painter G, Choi W-B & Liotta DC (1992a) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5- yl]cytosine. Antimicrobial Agents & Chemotherapy 36:2423-2431.
33. Schinazi RF, Boudinot FD, Ibrahim SS, Manning C, McClure HM & Liotta DC (1992b) Pharmacokinetics and metabolism of racemic 2′,3′-dideoxy- 5-fluoro-3′-thiacytidine in rhesus monkeys. Antimicrobial Agents & Chemotherapy 36:2432-2438.
34. Schinazi RF, Gosselin G, Faraj A, Korba BE, Liotta DC, Chu CK, Mathe C, Imbach J-L & Sommadossi J-P (1994) Pure nucleoside enantiomers ot β-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrobial Agents & Chemotherapy 38:2172-2174.
35. Schinazi RF, McMillan A, Lloyd Jr RL, Schlueter-Wirtz S, Liotta DC & Chu CK (1997) Molecular properties of HIV-1 resistant to (+)-enantiomers and racemates of oxathiolane cytosme nucleosides and their potential for the treatment of HIV and HBV infections. Antiviral Research 34:A42.
36. Ussery MA, Wood OL Kunder, SC, Bacho MA, Broud DD, Papermaster SF, Hall BE, Ciavarella A, Nielsen CJ & Schinazi RF (1995) Anti-HIV activity in the HuPBMC SCID mouse model of six novel nucleoside analogs: (-)-FTC, (±)-FTC, D-DAPD, D-D4FC, CS-92 and CS-87. Antiviral Research 26:A238.
37. Yeh KC & Kwan KC (1978). A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. Journal of Pharmacokinetics & Biopharmaceutics 6:79-98.